National Institute for Health and Care Excellence (NICE)

#Drug pricing #National Institute for Health and Care Excellence (NICE) #Rare disease

New NICE thresholds is good news for ultra-rare disease drugs, says biotech 

 The National Institute for Health and Care Excellence (NICE), the body that determines the clinical effectiveness and economic value of new medicines, has increased the cost-effectiveness thresholds it applies for drugs that qualify for their Highly Specialised Technology (HST) programme.  However, SynaptixBio, the only company licensed to commercialise a treatment for… Read More

#Business & Investment #News

#Alzheimer's #Association of the British Pharmaceutical Industry #National Institute for Health and Care Excellence (NICE) #UK

From the Editor: Not NICE enough

The recent decision by the National Institute of Health and Care Excellence (NICE) to reject two Alzheimer’s drugs on the basis of “not providing good value for money” was met with considerable disappointment.  Pharmaceutical company Eisai, developer of the rejected therapy lecanemab, was understandably disappointed , saying it was “deeply… Read More

#Exclusive Content

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Eisai #National Institute for Health and Care Excellence (NICE) #Neuroscience

NICE rejects Alzheimer’s drugs for lack of cost-effectiveness

The UK National Institute for Health and Care Excellence (NICE) has reached its final decision on two Alzheimer’s treatments, denying their use on the NHS due to the therapies not providing “good value for money.”  Eli Lilly’s donanemab and Eisai’s lecanemab were under final draft guidance by NICE, which had… Read More

#News #Regulatory #Trending News

Kidneys
#AstraZeneca #Chronic kidney disease (CKD) #Kidney disease #National Institute for Health and Care Excellence (NICE)

More patients to become eligible for chronic kidney disease treatment 

The UK National Institute for Health and Care Excellence (NICE) has published updated Final Draft Guidance recommending AstraZeneca’s Forxiga (dapagliflozin) as an option to treat chronic kidney disease (CKD) in adults in certain cases. This is the case if: It is an add-on to optimised standard care including the highest… Read More

#News

Drugs targeting amyloid Plaque
#Alzheimer's #Drug safety #Eisai #Monoclonal antibodies #National Institute for Health and Care Excellence (NICE)

Researchers call for extra safety monitoring of lecanemab

Researchers from the UK’s Drug Safety Research Unit are calling for the robust monitoring of the safety of lecanemab, a new drug to treat Alzheimer’s disease (AD).  In a review article, published in the British Journal for Clinical Pharmacology, the researchers discuss the need for ongoing assessment of the safety… Read More

#News #Regulatory #Trending News

Breast cancer cell
#Breast cancer #Cancer research #Gene mutation #National Institute for Health and Care Excellence (NICE) #Regulatory

NICE approves first ESR1-mutated metastatic breast cancer drug

Final draft guidance from the UK’s National Institute for Health and Care Excellence (NICE) recommends the use of elacestrant, the first tailored treatment for locally advanced and metastatic breast cancer with mutations in the ESR1 gene. Specifically, the drug will be available on the NHS to treat post-menopausal women, and… Read More

#Cancer Research #News #Regulatory

#Immunocore Holdings #National Institute for Health and Care Excellence (NICE) #Oncology #Ophthalmology

UK’s NICE reverses decision on uveal melanoma therapy

Immunocore Holdings’ Kimmtrak (tebentafusp) has been recommended for funding through the National Health Service (NHS) in England by the National Institute for Health and Care Excellence (NICE).  NICE has recommended KIMMTRAK within its marketing authorisation for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.   The recommendation overturns… Read More

#News #Regulatory

Dementia
#Alzheimer's #Drug development #Eli Lilly #Monoclonal antibodies #National Institute for Health and Care Excellence (NICE) #Regulatory

UK’s NICE rejects second disease-modifying therapy for Alzheimer’s 

UK regulator the National Institute for Health and Care Excellence (NICE) has ruled against the use of a second monoclonal antibody for Alzheimer’s disease, just two months after rejecting Eisai’s lecanemab (Leqembi).  NICE concluded that Eli Lilly’s donanemab (Kisunla) only provides a “small benefit”… Read More

#News

Lecanemab
#Alzheimer's #Eisai #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders #UK

UK regulator rules benefits of lecanemab do not justify the cost

The benefits of Alzheimer’s drug lecanemab (Leqembi) are too small to justify the cost of providing the treatment to NHS patients, the UK regulator has ruled. This was the decision by the National Institute for Health and Care Excellence (NICE) in draft guidance on the drug. Lecanemab is for slowing… Read More

#News #Regulatory #Trending News

Johnson & Johnson head office
#Bispecific therapeutics #GlobalData #Johnson & Johnson #Myeloma #National Institute for Health and Care Excellence (NICE)

J&J will dominate bispecific T-cell engager market

Tecvayli (teclistamab) has been recommended for relapsed and refractory multiple myeloma (RRMM) in England and Wales, leading analysts to predict Johnson & Johnson (J&J) will dominate the bispecific T-cell engagers (BiTEs) market by 2030. The UK National Institute for Health and Care Excellence (NICE) recommended teclistamab… Read More

#News

Multiple myeloma
#Blood cancer #Menarini #Myeloma #National Institute for Health and Care Excellence (NICE) #Oncology

Novel multiple myeloma drug recommended for UK NHS use

The UK’s National Institute for Health and Care Excellence (NICE) has published draft guidance recommending the use of Nexpovio (selinexor), in combination with bortezomib and dexamethasone, as a treatment for eligible multiple myeloma patients who have received one or two prior treatments. The recommendation follows recent NICE guidance recommending Nexpovio,… Read More

#News #Regulatory

CAR-T therapy
#Blood cancer #Leukaemia #National Institute for Health and Care Excellence (NICE) #Oncology #Paediatrics

UK’s NICE supports CAR-T for young people with leukaemia

The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Kymriah (tisagenlecleucel) for treating paediatric and young adults up to the age of 25 with B-cell acute lymphoblastic leukaemia (ALL). It is approved in cancers that are refractory, in relapse post-transplant or in second or later relapse. The… Read More

#News #Regulatory

Biliary tract
#AstraZeneca #Cancer research #National Institute for Health and Care Excellence (NICE) #NHS #Regulatory

Combination therapy recommended for NHS use for biliary tract cancer 

AstraZeneca has announced that the National Institute for Health and Care Excellence (NICE) has recommended Imfinzi (durvalumab) in combination with gemcitabine and cisplatin (chemotherapy) for NHS use in England and Wales for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer (BTC).1… Read More

#Covid-19 #News

Enzymes
#Chiesi #Enzymes #Genetic diseases #National Institute for Health and Care Excellence (NICE) #Rare disease

NICE okays enzyme replacement therapy for alpha-mannosidosis

Chiesi’s Lamzede (velmanase alfa) will now be funded on the NHS in England and Wales as an option for treating the non-neurological signs and symptoms of mild to moderate alpha-mannosidosis following a recommendation by the National Institute for Health and Care Excellence (NICE). The treatment must be started in people… Read More

#News #Regulatory

Myeloma cells
#Cancer research #Janns #Janssen #Myeloma #National Institute for Health and Care Excellence (NICE) #Oncology

UK regulator gives green light to combination for multiple myeloma

The National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (DLd) for untreated multiple myeloma (MM) for routine use on the NHS in England and Wales. The therapy is now recommended within an NHS setting for the treatment of adults with… Read More

#News #Regulatory

Stamp of approval
#Chiesi #National Institute for Health and Care Excellence (NICE) #Rare disease #UK

NICE recommends enzyme therapy for Fabry disease

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Elfabrio (pegunigalsidase alfa) as an option for treating Fabry disease (or alpha-galactosidase deficiency). The drug is recommended for use on the NHS under the terms of a confidential commercial agreement. Pegunigalsidase alfa is a novel enzyme replacement therapy… Read More

#News #Regulatory